FGLs

________________________________________________________________

FGLs is one of a family of compounds selected from the group of allosteric Fibroblast Growth Factor (FGF) receptor modulators referred to as FGL. FGL peptides have demonstrated positive regenerative effects in a number of in vivo models of neurodegeneration, such as beta-amyloid-induced toxicity, global ischemia and chronic stress. They have been shown to ameliorate impaired cognition in several animal models and to enhance learning and memory in intact adult animals. FGL peptides have also demonstrated antidepressant activity and neurogenesis. FGLs has been shown to prevent cognitive impairment in a double-transgenic animal model of Alzheimer's disease.

The in vivo effects of FGL suggest a dual effect: 1) potential disease-modifying activity in several neurodegenerative disorders, including Alzheimer's disease, and 2) a direct amelioration of impaired cognition. FGLs' direct and quickly detectable effect on cognition is expected to support its future clinical development as it may yield proof of relevant biological activity faster than is typically seen from regenerative treatments. This feature could give additional comfort to proceed with larger clinical trials needed to establish clinical proof of disease-modification for regulatory approval purposes.